Get the free version of Marbridge Daily delivered to your inbox

Click here to subscribe

Medical AI Imaging Firm VoxelCloud Wins RMB 100 Mln Series A+

Vcbeat, 9/28/17

Medical artificial intelligence imaging company VoxelCloud completed RMB 100 mln in Series A+ funding today, led by Chinese internet and mobile services firm Tencent (0700.HK) and with participation from Sequoia Capital and United Capital. The funding will be used to further integrate AI medical products with hospital scenarios.

VoxelCloud was founded in Los Angeles in 2015, and has teams in Shanghai and Suzhou. The company primarily uses AI and cloud computing technology to mine medical imaging and clinical data to help doctors analyze and diagnose diseases.

VoxelCloud's three primary product lines - lung cancer diagnosis, ophthalmology exams, and coronary CT analysis - are currently used by more than 50 hospitals in China and overseas, explained founder Ding Xiaowei. Since its launch, VoxelCloud has helped doctors diagnose approximately 50,000 patients with chest diseases, 50,000 patients with heart disease, and 100,000 patients with eye diseases.

VoxelCloud primarily partners with three categories of institutions: medical institutions, large-scale medical centers, and national screening programs; platform-based service providers; and device manufacturers. VoxelCloud make its services and technologies available on third-party service provider platforms, allowing its products to be used and verified in more cases. For hardware makers, Including VoxelCloud's analysis algorithms increases the value of medical devices for more differentiated pricing.

VoxelCloud's augmented coronary CT analysis product has been approved by the USA's FDA and Europe's CE certification for market access.

VoxelCloud previously won USD 8-digit Series A funding from Sequoia Capital and United Capital in May.

Keywords: VoxelCloud online healthcare VC M&A Ding Xiaowei Internet funding Tencent cloud computing Series A Sequoia Capital 0700.HK artificial intelligence United Capital

Feedback

Please note, all fields are required.
None of your personal information will be shared with third parties.

SendingSending

Disclaimer

The information contained in this newsletter is based upon sources that Marbridge Consulting believes to be reliable, and we have made every effort to translate the original articles or article excerpts as faithfully as possible. However, Marbridge Consulting makes no warranty of and assumes no legal responsibility for the accuracy of either the original source material or the English language translations.

Marbridge Daily Premium

Interested in gaining full access to all newsletter articles and the Marbridge Daily archive? To learn more about premium subscription options, including pricing, please:

Click here

Marbridge Consulting RSS Feed

Marbridge Reports